Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021
Neurology and Therapy · 2023-12 · 12 (6) · 1961-1979
DOI: 10.1007/s40120-023-00532-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 08.09.2023. Verfasst von Crystal Watson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Atara Biotherapeutics, Thousand Oaks, CA, USA. cwatson@atarabio.com. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Atara Biotherapeutics.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Atara Biotherapeutics, Thousand Oaks, CA, USA. cwatson@atarabio.com.
- Atara Biotherapeutics, Thousand Oaks, CA, USA.
- Adelphi Real World, Bollington, Cheshire, UK.
Förderung
- Atara Biotherapeutics
Zitieren
APA
Watson, C., Thirumalai, D., Barlev, A., Jones, E., Bogdanovich, S., & Kresa-Reahl, K. (2023). Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021. Neurology and Therapy, 12(6), 1961-1979. https://doi.org/10.1007/s40120-023-00532-2
Vancouver
Watson C, Thirumalai D, Barlev A, Jones E, Bogdanovich S, Kresa-Reahl K. Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021. Neurology and Therapy. 2023;12(6):1961-1979. doi:10.1007/s40120-023-00532-2
BibTeX
@article{Watson2023,
author = {Watson, Crystal and Thirumalai, Dhanalakshmi and Barlev, Arie and Jones, Eddie and Bogdanovich, Sasha and Kresa-Reahl, Kiren},
title = {Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021},
journal = {Neurology and Therapy},
year = {2023},
volume = {12},
number = {6},
pages = {1961--1979},
doi = {10.1007/s40120-023-00532-2}
}
EUVIMED